FDA lifts clinical hold on anthrax vaccine

The FDA has lifted the clinical hold on PharmAthene's ($PIP) anthrax vaccine candidate, SparVax. A Phase II trial was put on hold in August before enrolling a patient, but it can now begin after PharmAthene gave FDA more stability data. SparVax is a rival to Emergent BioSolutions' current and pipeline vaccines. Release | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.